Nurix Therapeutics, Inc. NRIX
We take great care to ensure that the data presented and summarized in this overview for Nurix Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NRIX
View all-
Black Rock Inc. New York, NY6.82MShares$68.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.5MShares$55.2 Million2.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$44.3 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.05MShares$40.7 Million5.06% of portfolio
-
Commodore Capital LP New York, NY3.98MShares$39.9 Million4.63% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$39 Million0.55% of portfolio
-
Wellington Management Group LLP Boston, MA3.19MShares$32 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.91MShares$29.3 Million0.0% of portfolio
-
State Street Corp Boston, MA2.86MShares$28.7 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD2.43MShares$24.4 Million0.02% of portfolio
Latest Institutional Activity in NRIX
Top Purchases
Top Sells
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Insider Transactions at NRIX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,198
-15.53%
|
$68,178
$11.33 P/Share
|
|
Apr 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,438
-5.76%
|
$26,818
$11.5 P/Share
|
|
Apr 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+6.79%
|
-
|
|
Apr 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,894
-7.2%
|
$31,834
$11.5 P/Share
|
|
Apr 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+6.34%
|
-
|
|
Apr 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,377
-5.2%
|
$37,147
$11.5 P/Share
|
|
Apr 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,956
+4.59%
|
-
|
|
Mar 03
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,825
-7.5%
|
$81,550
$14.77 P/Share
|
|
Jan 31
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-7.54%
|
$115,200
$20.21 P/Share
|
|
Jan 31
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+6.65%
|
$5,760
$1.86 P/Share
|
|
Jan 30
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,220
-4.54%
|
$64,400
$20.07 P/Share
|
|
Jan 30
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,674
+7.13%
|
-
|
|
Jan 30
2025
|
Gwenn Hansen Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,690
-3.11%
|
$73,800
$20.07 P/Share
|
|
Jan 30
2025
|
Gwenn Hansen Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,957
+5.0%
|
-
|
|
Jan 30
2025
|
Hans Van Houte Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,811
-3.34%
|
$56,220
$20.07 P/Share
|
|
Jan 30
2025
|
Hans Van Houte Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,636
+6.79%
|
-
|
|
Jan 02
2025
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$109,440
$19.5 P/Share
|
|
Jan 02
2025
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|
|
Dec 02
2024
|
Christine Ring Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,760
-17.02%
|
$120,960
$21.73 P/Share
|
|
Dec 02
2024
|
Christine Ring Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,760
+14.54%
|
$5,760
$1.86 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 173K shares |
|---|
| Open market or private sale | 168K shares |
|---|---|
| Bona fide gift | 54K shares |